A Study to Investigate the Time to Onset of Action of 10 mg and 20 mg of Vardenafil Compared to Placebo in Males With Erectile Dysfunction

Overview

This purpose of the study was to evaluate the earliest time to onset of action in adults with erectile dysfunction (often called impotence). In this study vardenafil has been compared to placebo. Patients were asked to fill in questionnaires and a diary in which they filled in details about attempts at sexual activity during study period. Patients received also a stopwatch to record the time of onset of erection. Stopwatch should be started immediately prior to initiating sexual activity and stopped when an erection perceived to be adequate for penetration was obtained.

Full Title of Study: “A Randomized, Double Blind, Double Dummy, Parallel Group, Multi-center Study to Investigate the Time to Onset of Action of 10 mg and 20 mg of Vardenafil Compared to Placebo in Males With Erectile Dysfunction.”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Double (Participant, Investigator)

Interventions

  • Drug: Levitra (Vardenafil, BAY38-9456)
    • Vardenafil 10 mg and 20 mg orally once a day as needed
  • Drug: Placebo
    • Matching Placebo

Arms, Groups and Cohorts

  • Experimental: Arm 1
  • Placebo Comparator: Arm 2

Clinical Trial Outcome Measures

Primary Measures

  • – Earliest elapsed time from dosing to attainment of an erection perceived to be adequate for penetration leading to completion of successful intercourse as measured by Sexual Encounter Profile Question 3 (SEP 3)
    • Time Frame: First four doses with successful intercourse

Secondary Measures

  • – Earliest elapsed time from dosing to attainment of an erection perceived to be adequate for penetration as measured by Sexual Encounter Profile Question 2 (SEP 2).
    • Time Frame: among the first four doses
  • – The erectile function (EF) domain score of the International Index of Erectile Function (IIEF) calculated as the sum of scores from Questions 1-5 and 15 at Week 4 as well as all other IIEF factor subscores.
    • Time Frame: among the first four doses
  • – Responder time to onset, where onset is time from dosing to attainment of an erection perceived to be adequate for penetration.
    • Time Frame: among the first four doses
  • – Other diary questions
    • Time Frame: among the first four doses
  • – Safety and tolerability
    • Time Frame: within the study duration

Participating in This Clinical Trial

Inclusion Criteria

  • Males with ED for more than 6 months according to the NIH Consensus statement(inability to attain and/or maintain penile erection sufficient for satisfactory sexual performance) – Heterosexual relationship – 18 years and older Exclusion Criteria:

  • Primary hypoactive sexual desire – History of myocardial infarction, stroke or life threatening arrhythmia within the prior 6 months – Nitrates or nitric oxide donors use – Other exclusion criteria according to the US Product Information

Gender Eligibility: Male

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Bayer
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Bayer Study Director, Study Director, Bayer

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.